

2nd annual
stem cell meeting on the mesa

Friday, October 19, 2007
The Salk Institute for Biological Studies
Frederic de Hoffmann Auditorium

presented by
The San Diego Consortium
for Regenerative Medicine

Lead Sponsor

invitrogen™

Managed by

CONNECT®



2nd annual stem cell meeting on the mesa

Friday, October 19, 2007

8:00 am **Registration and Networking** – Auditorium Foyer – Continental Breakfast

9:00 am **Welcome** – Auditorium

Fred H. Gage, Salk Institute for Biological Studies

9:15 am **Panel 1 – Basic Science: Recent Scientific Progress and Ideas**

Chair: Juan Carlos I. Belmonte, Salk Institute for Biological Studies

Panel: Mark Mercola, Burnham Institute for Medical Research
Rob O'Brien, University of California, San Diego
Todd Macfarlan, Salk Institute for Biological Studies
Rhiannon Nolan, University of California, San Diego
Justin Voog, University of California, San Diego and
Salk Institute for Biological Studies

10:30 am **Break**

10:45 am **Panel 2 – Technologies: New Methods and Advances in Technology**

Chair: Evan Snyder, Burnham Institute for Medical Research

Panel: Senyon Choe, Salk Institute for Biological Studies
Jon Chesnut, Invitrogen
Dave Brafman, University of California, San Diego
Gene Yeo, Salk Institute for Biological Studies
Gregg Duester, Burnham Institute for Medical Research

12:00 pm **Lunch & Poster Session** – Auditorium Foyer

The Salk Institute for Biological Studies
Frederic de Hoffmann Auditorium



1:00 pm **Roundtable Discussion: Independent Citizens' Oversight Committee Board Members on the Current State of the California Institute for Regenerative Medicine**

Chair: Roger Bingham, The Science Network

Panel: Floyd Bloom, The Scripps Research Institute
Robert Klein, Chair, Independent Citizens' Oversight Committee, CIRM
John Reed, Burnham Institute for Medical Research
Duane Roth, CONNECT
Janet Wright, American College of Cardiology/ICOC

2:00 pm **Panel 3 – The San Diego Perspective: The State of Stem Cell Product Development**

Chair: Joydeep Goswami, Invitrogen

Panel: Jeff Krstich, International Stem Cell Corporation
Steve Laderman, Agilent Technologies
Alan Lewis, Novocell
Joe Panetta, BIOCOM
Kai Pinkernell, Cytori Therapeutics

3:15 pm **Break**

3:30 pm **Panel 4 – Preparing for Clinical Trials: Ethical and Regulatory Considerations**

Chair: Mike Kalichman, University of California, San Diego

Panel: Cathryn Campbell, Needle & Rosenberg, PC
Ted Friedmann, University of California, San Diego
Fred H. Gage, Salk Institute for Biological Studies
Catriona Jamieson, University of California, San Diego
Janet Wright, American College of Cardiology/ICOC

4:45 pm **Poster Session & Networking Cocktail Reception** – Auditorium Foyer

Lead Sponsor

invitrogen™

Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics and cell biology, as well as emerging fields such as stem cell science – placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more then 70 countries around the world. The company globally employs approximately 4,300 professionals and had revenues of more than $1.15 billion in 2006.

For more information, visit *www.invitrogen.com* or *www.invitrogen.com/stemcell.*

VIP Dinner Sponsor

LATHAM & WATKINS LLP

Latham & Watkins is one of the world's largest and most respected full-service law firms, with a global network of more than 1900 lawyers in 24 global locations. With over 100 attorneys in two San Diego locations, we stand ready to address the entire spectrum of life science, pharmaceutical and biotechnology issues for start-ups to multinational conglomerates, as well as the investment banks and venture capital firms that serve them.

Our services include: Raising Capital, Mergers & Acquisitions, Protecting Intellectual Property, Strategic Partnership & Licensing Agreements and Complex Litigation.

Latham's expertise and connections are critical to your company's growth – offering global solutions to your complex business and legal issues.

Luncheon Sponsor

Molecular Diagnostic Services

Molecular Diagnostic Services, Inc. (MDS) has been an independent CRO since 1992. On the cutting edge of technology for 1.5 decades, MDS offers services in the many phases of stem cell research and therapy. We are prepared to serve as a non-GLP/GMP or strictly as a GLP/GMP lab.

We can culture adult or embryonic stem cells and monitor the differentiation markers for your therapy development. Our scientists can help clients to develop stems cells that synthesize their therapeutic molecule by initiating differentiation and monitoring specific production. A selected list of our services include:

- Gene Expression
  - o FACS Analysis
  - o Immunohistochemistry
  - o RT-PCR
- Colony Forming Cell (CFC) Assays
- In Vitro Pluripotency
- In Vivo Pluripotency
- Differentiation potential
- Lineage specificity
- Cell Line Characterization
- Cell Line Identity
- Genetic Stability
- Genotyping
- Authentication

Additional Services:

- PCR Testing for Human Viruses
- Contaminants
- Adventitious Agents

Cocktail Reception Sponsor

Pfizer

Pfizer La Jolla is part of Pfizer Global Research and Development (PGRD) and one of Pfizer's major research and development sites around the globe. The 1,000 scientists and staff at the La Jolla site focus on discovering and developing new medicines to treat many forms of cancer and diseases of the eye (e.g. glaucoma and macular

degeneration). In 2006, the FDA approved Sutent, a drug developed at Pfizer La Jolla, for treating stomach and kidney cancers.

In 2007, Pfizer launched a new 28,000-square-foot incubator facility on its La Jolla campus with eight high-tech chemistry and biology labs as well as adjoining office space. Pfizer will invest $10 million a year in The Pfizer Incubator, supporting life science start-ups that are working on projects related to the company's prime therapeutic areas. In addition, Pfizer is investing $100 million over five years in a research collaboration with The Scripps Research Institute to advance scientific knowledge about today's incurable diseases and novel ways to treat them.

Webcast Sponsor

THE WAITT FAMILY FOUNDATION
HELPING GOOD PEOPLE DO GREAT THINGS

The Waitt Family Foundation is a charitable organization based in La Jolla, CA. The Foundation makes grants to programs that help us understand our past, improve the present, and prepare for the future. The Foundation funds partnerships and projects that seek a deeper understanding of human history, expand the potential of the human mind, and improve mankind's knowledge through historical and scientific exploration.

The Foundation was established in 1993 by Ted and Joan Waitt as a vehicle for "helping good people do great things." Both Ted and Joan grew up in close-knit families with strong ties to their communities. They credit much of their success and good fortune in life to the values they learned at home. The Foundation was originally based in North Sioux City, South Dakota, where the Waitt family has a 100-year history of community involvement and leadership shared by Ted's father and grandfather. It was here that the Waitt family, over the course of four generations, acquired time-tested core values of respect for family, concern for community, and commitment to hard work. Since 1999, the Foundation's main office has been located in La Jolla, CA.

Media Sponsor

Rebecca & John Moores

John Moores grew up in Texas and attended public schools there. After high school he married his high school sweetheart, Becky, and worked full-time as a computer programmer to support his young family. He has no formal education in computers or software development; he gained all of his knowledge and expertise on the job. He and his wife attended the University of Houston at night, and each received two degrees from that university.

In 1980, Moores founded BMC Software, Inc. as its sole shareholder and first programmer. He wrote the initial, highly successful software products at BMC and built BMC into a significant competitor in the computer software industry. Moores continues to be active in providing his creative talents for the development of computer software for many new start-up software companies.

In 1994, Moores purchased the San Diego Padres Baseball Club. Since his purchase of the team, the Padres have won two National League Western Division championships and one National League championship. Moores serves on Major League Baseball's Executive Council and on the board of directors of Major League Baseball Advanced Media.

Moores' professional life is complemented by his extensive humanitarian work. He has given much of his time and own personal wealth to a wide variety of causes around the globe. He also has become a major contributor to San Diego's sports, civic, cultural and educational communities. Moores currently serves on the boards of a number of institutions that are important to San Diego, including the University of California Board of Regents (Chairman, 2002-2004), The Scripps Research Institute (Chairman), UCSD Foundation, Campanile Foundation of San Diego State University and the San Diego Hall of Champions Advisory Board.

As Chairman of The Carter Center, Moores succeeded President Carter and is carrying on the work that touches the lives of people in more than 65 countries, primarily in the poorest countries in sub-Saharan Africa, through its disease intervention, election monitoring, agriculture, public health training, mental illness advocacy, and civil and international conflict prevention programs.

Panel Sponsors

Agilent Technologies

Agilent Technologies is a leading provider of instrumentation, supplies, software and services to the life sciences. Agilent's 25,000+ customers range from global pharmaceutical corporations to biotech companies, government labs and academic researchers. With $1.55 billion in revenue in fiscal year 2006, Agilent LSCA has approximately 4,000 employees worldwide and provides global sales, support and manufacturing. LSCA's major sites are in California, Delaware, Shanghai, Tokyo and Germany.

Agilent tools help scientists to understand complex biological processes, unlock the causes of disease and speed the discovery of new drugs. Agilent provides products throughout the entire pharmaceutical value chain from basic research to drug manufacturing quality control.

In the LIife Science Markets, Agilent's products and services specifically address the needs of five key markets: genomics, proteomics, metabolomics, bioinformatics, and pharmaceutical analysis.

In Genomics research, Agilent's offering enables scientists to compare the gene activity of diseased versus healthy cells, providing insight into the genetic causes of disease. Agilent is a leading provider of microarray solutions and is particularly successful in supporting emerging genomic research techniques.

Bioinformatics enables scientists to pull together disparate sets of highly complex biological data and analyze the information. Agilent offers a range of informatics solutions spanning applications in gene expression, genotyping and protein identification. The GeneSpring family of bioinformatics systems is considered the industry's gold standard.

Cytori Therapeutics

Cytori Therapeutics is a global leader in the development and commercialization of regenerative medicine products. The company is developing therapeutic applications for its Celution™ System to enable real-time regenerative cell therapy in conjunction with breast reconstruction surgery, cardiovascular disease, and other unmet medical needs. The Company's StemSource™ Cell Bank, which is based on Cytori's innovative Celution™ System, is being commercialized in Japan to hospitals and clinics to enable regenerative cell banking. *www.cytoritx.com.*

International Stem Cell Corporation

International Stem Cell Corporation (ISCO), based in Oceanside, California, is a biotechnology company focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be "differentiated" into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. For more information, contact Jeff Krstich, CEO, at 760-940-6383 or visit the ISCO website at: *www.internationalstemcell.com.*

Novocell, Inc. (San Diego and Athens, Georgia) is a private stem cell engineering company creating, delivering and commercializing cell and drug therapies for diabetes and other chronic diseases.

Novocell is the first company to efficiently engineer human embryonic stem cells (hESCs) into definitive endoderm, the gatekeeper cells that differentiate into pancreas, liver, lung and many other cells, tissues and organs. This provides a platform to create cell therapies, develop drug discovery opportunities in regenerative medicines, and assays for ADME/toxicity, as well as find therapies that target key cancer stem cells.

Novocell utilizes a biocompatible polyethylene glycol (PEG) conformal coating that enables transplanted cells to survive and function by protecting them from immune rejection. It is designed to eliminate the need for continuous immunosuppressant drugs that are necessary for allograft transplants. The technology is being used in the current proof-of-principle primary islet transplant phase 1/2 clinical trial in type 1 diabetics.

PR Sponsor

L7 CREATIVE COMMUNICATIONS

L7 Creative provides powerful creative ideas for progressive brands and integrates them into advertising solutions. We combine the expertise of a full-service advertising agency with the interactive skills of a digital shop.

As a "one-stop shop," we drive brand consistency across both traditional and digital media. Our full-scope approach eliminates the need to engage multiple specialty vendors. The payoff for you is streamlined communication,improved efficiency, brand consistency, and ultimately, increased ROI.

We have a proven reputation for building innovative brands that achieve market leadership. Stunning creative work and superior customer service -that's what you get from the L7 Creative team. Thinking Big? Think Square. *www.L7creative.com*

The San Diego Consortium for Regenerative Medicine

Four of the nation's most preeminent research institutions, all based in San Diego, have joined forces to establish an independent, non-profit consortium dedicated to stem cell research that in time will lead to promising new medical discoveries and treatments. The Burnham Institute for Medical Research, The Salk Institute for Biological Studies, The Scripps Research Institute and the University of California, San Diego joined together to work toward establishment and operation of an entity called the San Diego Consortium for Regenerative Medicine (SDCRM).

SDCRM operates as a nonprofit public benefit corporation and is governed by a board of directors comprised of prominent community members and a representative from each participating institution. Board members include: Malin Burnham, John Davies, Sharon Davis, Marye Anne Fox (UCSD), Lawrence Irving, Irwin Jacobs, Jessie Knight, Jr., Richard Lerner (Scripps), Alberto Mier y Teran, John Moores, Richard Murphy (Salk), John Reed (Burnham), Lynn Schenk, Theodore Waitt, and Gayle Wilson.

SDCRM boasts extraordinary intellectual capital: 95 National Academy of Sciences members; 14 Nobel Prizes, over 200 companies founded, and 24 products commercialized. Ed Holmes, leads the Consortium as President and CEO and serves as Executive Deputy Chairman of the Biomedical Research Council, and the Executive Chairman of the National Medical Research Council, A*STAR, both located in Singapore. Previously, Dr. Holmes was the vice chancellor for health sciences and dean of the School of Medicine at UC San Diego as well as a member of the Independent Citizens Oversight Committee, the governing body for CIRM. Scientific leaders from each institute developed the Consortium's scientific vision and plan: Fred "Rusty" Gage (Salk); Martin Friedlander (Scripps); Larry Goldstein (UC San Diego); and Evan Synder (Burnham).

The alliance has the potential to stimulate the region's economy through infusion of CIRM funding, private grants, philanthropic funds and other resources that might not otherwise flow into the region. These resources include funding, training opportunities, and access to global markets for students and graduates. The Consortium will also pursue joint funding to support its collaborative projects.

BURNHAM INSTITUTE *for* MEDICAL RESEARCH
From Research, the Power to Cure

THE SCRIPPS RESEARCH INSTITUTE

SALK INSTITUTE FOR BIOLOGICAL STUDIES

UCSD

BIOCOM

BIOCOM is the largest regional life science industry association in the world, representing more then 500 members. To ensure San Diego's continued success, we focus on initiatives that positively influence the growth and success of the life science industry—including capital formation, public policy, workforce development, and scientific discovery and development. The association acts as a news and information hub for the entire biocommunity in San Diego, and creates cost-saving member services such as the Purchasing Group.

Our membership includes industry companies pioneering new biopharmaceutical technologies, medical devices and diagnostics; the presence and commitment of the world's most successful Big Pharma companies; top research and academic institutions of the world—The Burnham Institute, The Salk Institute, The Scripps Research Institute, and U.C. San Diego; and leading service providers in the areas of intellectual property, workforce development, marketing, information technology, clinical and regulatory management, facility/environmental engineering, finance, etc.

BIOCOM's membership and San Diego's life science cluster creates an ecosystem of innovation—an environment conducive for life science companies accelerating their success in bringing life saving products to patients. With the proximity of many of San Diego's life science companies within 10 minutes of each other, San Diego is the most highly concentrated life science cluster in the U.S., and provides a unique collaborative environment.

San Diego boasts the most R&D assets[1] of all other metropolitan areas, approximately 39,000 life science jobs[2], and more than 300 products in preclinical or clinical development. This region has the highest concentration of Nobel Laureates and the highest number of Ph.D's per capita.

For more information about BIOCOM please visit our website at *www.biocom.org.*

1. San Diego Chamber of Commerce 2. Milken Institute Report, 2004

CONNECT®

CONNECT is a non-profit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. Since 1985, CONNECT has assisted in the formation and development of over 1,000 companies and is widely regarded as the nation's most successful regional program linking inventors and entrepreneurs with the resources they need for success.

CONNECT programs are targeted toward inventors and entrepreneurs and are delivered with the assistance of its broad membership base in three major areas: new company creation, training and education, and recognition of the best in innovation.

Originally founded by the University of California, San Diego, CONNECT has a dual role in accelerating growth: it provides added value and delivers targeted, high-level expertise to San Diego's technology business community by teaming up with the region's most prominent industry-specific organizations and individuals, and by partnering with world-class UC San Diego resources, such as the School of Medicine, Jacobs School of Engineering, San Diego Super Computer Center, and the Scripps Research and Salk Institutes.

Please visit *www.connect.org* for further information about CONNECT's mission, programs and events.

tsn thesciencenetwork

Imagine turning on your television—any time of day or night—and watching a heated debate about the impact of science on your life: from stem cell research and cloning to the use of genetically modified organisms (GMOs) in your food. From the biology of violence to the chemistry of addiction. From the puzzles of depression to the latest breakthroughs on aging. From the evolution of morality to the complexities of consciousness. From the exploration of space to the discovery of life beyond Earth.

Imagine eavesdropping on scientific meetings and Congressional hearings—getting the background buzz about science and its impact on social issues from education, ethics, and economics to law, psychology and religion.

Imagine a network that delivered the latest lecture by Stephen Hawking on the nature of time or by Jane Goodall on the chimpanzees of Gombe. Or archived

footage of the late Richard Feynman mesmerizing an audience with his Nobel-wattage intellect and irreverent humor. Perhaps you would find yourself in the midst of a marathon reprise of landmark television series like Carl Sagan's Cosmos or Jacob Bronowski's The Ascent of Man, rescued from retirement. Maybe a showing of Life Story, the dramatization of James Watson and Francis Crick's discovery of the double helix of DNA—or a Nova marathon. You might be taken into classrooms where America's star science teachers hold young minds spellbound with tales of our continuing odyssey to make sense of the natural world.

Put it all together and you have The Science Network (TSN). A C-SPAN for science. Visit *www.tsntv.org* for further information.

Thank you to those who have contributed time and energy to make this day possible.

Juan Carlos I. Belmonte, Salk Institute for Biological Studies

Roger Bingham, The Science Network

Fred Gage, Salk Institute for Biologocl Studies

Larry Goldstein, University of California, San Diego

Joydeep Goswami, Invitrogen

Mike Kalichman, University of California, San Diego

Joe Panetta, BIOCOM

Duane Roth, CONNECT

Evan Snyder, Burnham Institute for Medical Research



2nd annual stem cell meeting on the mesa

presented by The San Diego Consortium for Regenerative Medicine

BURNHAM INSTITUTE *for* MEDICAL RESEARCH
From Research, the Power to Cure

THE SCRIPPS RESEARCH INSTITUTE

SALK INSTITUTE FOR BIOLOGICAL STUDIES

UCSD

in partnership with

BIOCOM

CONNECT

tsn thesciencenetwork

---

lead sponsor

invitrogen™

---

supporting sponsors

LATHAM & WATKINS LLP

Pfizer

THE WAITT FAMILY FOUNDATION
HELPING GOOD PEOPLE DO GREAT THINGS

REBECCA & JOHN MOORES

Molecular Diagnostic Services

Agilent Technologies

Cytori Therapeutics

novocell

INTERNATIONAL STEMCELL CORPORATION

L7 CREATIVE COMMUNICATIONS



Today's community forum and webcast will bring together scientists, life science business executives, and government officials to learn about the exciting stem cell research initiatives underway in San Diego. Presenters representing the San Diego Consortium for Regenerative Medicine – Burnham Institute for Medical Research, Salk Institute for Biological Studies, The Scripps Research Institute, and the University of California, San Diego – and emerging companies will present cutting-edge research and discuss the scientific, ethical and business challenges facing the industry.